220 related articles for article (PubMed ID: 32920739)
1. Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
Lin Y; Lin L; Fu F; Wang C; Hu A; Xie J; Jiang M; Wang Z; Yang L; Guo R; Yang P; Shen H
Breast Cancer Res Treat; 2021 Jan; 185(1):39-52. PubMed ID: 32920739
[TBL] [Abstract][Full Text] [Related]
2. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
[TBL] [Abstract][Full Text] [Related]
3. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
Velloso FJ; Campos AR; Sogayar MC; Correa RG
BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
[TBL] [Abstract][Full Text] [Related]
4. Eugenol modulates the NOD1-NF-κB signaling pathway
Shi X; Zhang W; Bao X; Liu X; Yang M; Yin C
Front Endocrinol (Lausanne); 2023; 14():1136067. PubMed ID: 36923216
[TBL] [Abstract][Full Text] [Related]
5. Triple Negative Breast Cancer Detection Using LC-MS/MS Lipidomic Profiling.
Eghlimi R; Shi X; Hrovat J; Xi B; Gu H
J Proteome Res; 2020 Jun; 19(6):2367-2378. PubMed ID: 32397718
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer.
Shi X; Liu C; Zheng W; Cao X; Li W; Zhang D; Zhu J; Zhang X; Chen Y
Mol Cell Proteomics; 2024 Jan; 23(1):100703. PubMed ID: 38128647
[TBL] [Abstract][Full Text] [Related]
8. Comparative Profiling of Triple-Negative Breast Carcinomas Tissue Glycoproteome by Sequential Purification of Glycoproteins and Stable Isotope Labeling.
Chen X; Wu J; Huang H; Ding Q; Liu X; Chen L; Zha X; Liang M; He J; Zhu Q; Wang S; Xia T
Cell Physiol Biochem; 2016; 38(1):110-21. PubMed ID: 26742121
[TBL] [Abstract][Full Text] [Related]
9. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
10. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
[TBL] [Abstract][Full Text] [Related]
11. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
12. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
13. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
14. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
15. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer.
Xu JH; Zhao JX; Jiang MY; Yang LP; Sun ML; Wang HW
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3122-3129. PubMed ID: 32271430
[TBL] [Abstract][Full Text] [Related]
16. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
Wen DJ; Ren XJ; Dong LJ; He Y; Li XR
Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):769-776. PubMed ID: 31607066
[No Abstract] [Full Text] [Related]
17. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.
Liu AN; Sun P; Liu JN; Yu CY; Qu HJ; Jiao AH; Zhang LM
Tumour Biol; 2014 Oct; 35(10):9751-7. PubMed ID: 24972967
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer.
Li S; Li X; Yang S; Pi H; Li Z; Yao P; Zhang Q; Wang Q; Shen P; Li X; Ji J
Mol Cell Proteomics; 2021; 20():100121. PubMed ID: 34265469
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of cathepsin S expression by HSP90 and 5-HT
Gautam J; Bae YK; Kim JA
Breast Cancer Res Treat; 2017 Jan; 161(1):29-40. PubMed ID: 27796714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
